Designing the Next Generation of Radiopharmaceutical Pipelines

Targeted radiopharmaceuticals are entering a new phase of competition and innovation. With 298 programs now in preclinical development, pipelines are expanding rapidly, yet activity remains concentrated around a relatively small number of established targets.

As more programs compete for differentiation, the 3rd TRP Target Selection & Drug Design Summit (February 23–25 | Boston) is the only industry-focused meeting purpose-built for drug-developers to understand which targets, isotopes and drug design strategies will define the next generation of clinically and commercially successful radiopharmaceuticals.

Join 100+ scientific, technical and strategic leaders across biotech, pharma, regulations and academia to tackle the scientific and strategic challenges underpinning radiopharmaceutical target selection and drug design.

Your Dose of TRP Target Selection & Drug Design:

Mine Other Oncology Modalities for the Next RLT Target
For the first time, explore how clinical validation from ADCs, T-cell engagers, bispecifics, RDCs and companion diagnostics can be leveraged to identify high-potential RLT targets faster and how to translate this to the clinic

Fireside Chat ‘How Much Preclinical Evidence Is Enough?’
Benchmark approaches with Bayer and an ex-FDA regulatory expert to determine which preclinical studies are decision-critical, where additional data adds limited value and how to establish a clearer path towards IND.

Harness Kinetic Imaging to Make Better Target Decisions
Go beyond static uptake with total-body PET, digital SPECT, computational biology and multi-omics to interrogate target expression, heterogeneity, retention and biodistribution to characterize emerging targets with higher-confidence

Look Beyond the Usual Targets
Cross-examine emerging biology across the ECM, immune targets, brain, CAIX and beyond, while challenging conventional assumptions around receptor density, internalization and replenishment to expand the pool of viable RLT targets.

Optimize Radiopharmaceutical Drug Design
Connect target biology with targeting moiety, binder, radionuclide, linker and chelator selection to optimize biodistribution, tumor retention and therapeutic potential, and design more differentiated candidates from the outset.

Select the Right Radionuclide for the Right Biology
Interrogate the trade-offs between alpha and beta emitters and determine how radionuclide properties should inform molecular design, dosimetry, radiobiology and development strategy to maximize the therapeutic window.

With expertise from AstraZeneca, Bayer, Pfizer, Molecular Partners, Affibody, Ratio Therapeutics, Matrisome Bio, Harvard Medical School, University of Pennsylvania, ex-FDA and more.

If you're working to push a candidate towards the clinic, expand your target landscape, mine other modalities for clinically validated targets, select the right radionuclide, optimize your drug design or strengthen your preclinical package, this is the room to be in.

Join the industry's only meeting dedicated exclusively to the earliest and most consequential stages of RLT development, and benchmark the science and strategy that will define the next generation of differentiated radiopharmaceuticals.